GT Biopharma (GTBP) Stock: A Strong Buy On TriKE Data

GT Biopharma GTBP Stock News

GT Biopharma Inc (OTCMKTS: GTBP) is setting the stage for a strong day ahead in the market today, and for good reason. The company issued a press release announcing positive data from an oncology clinical trial. However, with the product also being assessed as a potential option to treat the novel coronavirus, this is likely to grab the attention of investors. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

GTBP Announces Successful Dosing

As mentioned above, GT Biopharma issued a press release this morning. IN the release, the company announced that it had successfully completed dosing of the first patient in its GTB-3550 Phase 1/II clinical trial. The trial is assessing the treatment as a potential option for acute myeloid leukemia, also known as AML.

During the trial, all enrolled patients will receive a single course of GTB-3550. Importantly, the first patient enrolled was already treated at a dose of 5µg/kg/day GTB-3550. To date, there have been no adverse events recorded either during the course of therapy or after. Moreover, the therapy is showing strong signs of efficacy.

In fact, GTBP said that the patient achieved stale disease with respect to the number of AML blasts observed before and after therapy. Also, this patient saw an increase in total NK cell population, attributable to the IL-15 component of the TriKE molecule. Moereover, there was no increase of any hyper-active T-cell population which could have resulted in cytokine storm or other T-cell associated toxicities.

In a statement, Anthony Cataldo, Chairman and CEO at GTBP, had the following to offer:

We are pleased to see such a positive result in our first patient being administered GTB-3550. We remain optimistic that GTB-3550 will continue to demonstrate therapeutic benefit in AML cancer patients with advanced disease. We believe the robustness of the TriKE™ platform allows us to use it to develop therapeutics for the treatment of other cancers and certain infectious diseases including HIV and coronavirus infections.

Why This News Is So Exciting

We’ll get to why this is so exciting from a coronavirus perspective in a minute. First, let’s talk about the company’s work in AML.

This particular patient was diagnosed with AML some time ago. Following diagnosis, the patient tried several prior lines of therapy with none of them working. So, not only is AML a very difficult to treat cancer, this late stage patient was on the short end of the stick. As such, generating a stable disease response is nearly unheard of. The fact that GT Biopharma was able to do this with their TriKE candidate is far above and beyond a positive signal.

It’s also important to keep in mind just how serious of a prognosis AML is. The cancer will infect somewhere between 3% and 5% of the adult population, with about 72.6% of those who develop the cancer, perishing as a result.

The AML market offers a tremendous opportunity for GTBP as well. While the company’s market cap is around $12 million, it is embarking on a market that experts suggest will be worth more than $3 billion annually by 2024.

Now, let’s talk about the coronviarus. The company recently announced a partnership under which it will be assessing its TriKE technology as a potential option in treating COVID-19. Essentially, the fact that the condidate gets Natural Killer, or NK, cells going suggests that it can assist in the treatment of a wide range of ailments and will most likely be incredibly effective in the treatment of the coronavirus.

With strong safety and efficacy signals early on in the AML trial, the light at the end of the tunnel is only getting brighter with regard to this drug across all areas that it is being studied. I’m expecting to see similar results as testing as an agent to combat COVID-19 begins.

With such strong results in AML, work to bring this treatment to AIDS patients, and a high liklihood of efficacy in COVID-19, GTBP is onto something with its TriKE technology and investors should be paying close attention.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story!

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required

Disclosure – The author is not an investment advisor or broker dealer. CNA Finance, parent company to Alpha Stock News was compensated fifteen thousand dollars to provide research, writing and digital outreach services to GT Biopharma. 

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.